These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29101359)

  • 1. Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab.
    Butterfield JT; Kim H; Knauer DJ; Nevala WK; Markovic SN
    Sci Rep; 2017 Nov; 7(1):14476. PubMed ID: 29101359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Targeted Chemotherapy for the Treatment of Melanoma.
    Nevala WK; Buhrow SA; Knauer DJ; Reid JM; Atanasova EA; Markovic SN
    Cancer Res; 2016 Jul; 76(13):3954-64. PubMed ID: 27197186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin-bound paclitaxel-derived albumin from human serum.
    Sato T; Okazaki M; Sano J; Kato C; Shimizu K; Kitagawa M
    Biomed Rep; 2021 Apr; 14(4):35. PubMed ID: 33732454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20
    Nevala WK; Butterfield JT; Sutor SL; Knauer DJ; Markovic SN
    Sci Rep; 2017 Apr; 7():45682. PubMed ID: 28378801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
    Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP
    J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
    Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
    Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.
    Rahman HT; Yeh S; Bergstrom CS
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):360-2. PubMed ID: 23061416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
    Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
    Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
    Kouchakzadeh H; Safavi MS; Shojaosadati SA
    Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
    Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
    Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing.
    Lakayan D; Haselberg R; Gahoual R; Somsen GW; Kool J
    Anal Bioanal Chem; 2018 Dec; 410(30):7837-7848. PubMed ID: 30328504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
    Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
    Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol.
    Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS
    J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.